The Pathogen Box project

Modeled after the Malaria Box, the Pathogen Box will contain ~400 diverse, drug-like molecules active against neglected diseases of interest and will be available free of charge at the end of 2015. Upon request, researchers around the world will receive a Pathogen Box of molecules to help catalyse neglected disease drug discovery. In return, researchers are asked to share any data generated in the public domain within 2 years, creating an open and collaborative forum for neglected diseases drug research.

What's happening with the Pathogen Box

The European Bioinformatics Institute’s open access database, (ChEMBL17) was analyzed and triaged to identify active chemotypes against the diseases of interest. In parallel partners from many disease areas were approached to share their expertise and contribute quality hit molecules or screening platforms. This effort has led to an initial list of 819 diverse chemotypes.

In June 2014, a Scientific Selection Committee (see below) composed of leading figures in medicinal chemistry reviewed the initial set of compounds to select 635 chemotypes termed as the “beta-set”.

These compounds are now being procured or synthesized for confirmatory screening.

Contribute to the Pathogen Box

It is not too late if you want to send us your ideas and suggestions on potential drug-like chemical scaffolds with activity against any of the pathogens to be considered for inclusion in the Pathogen Box.

All submissions will remain confidential until the launch of the Pathogen Box planned in Q4 2015. Also contributions will be acknowledged on this website.

The next review of the suggested compounds will occur in Q1 2015.

Diseases of Interest

Ascariasis, Buruli ulcer, Chagas, Cryptosporidiosis, Hookworm, Human African Trypanosomiasis, Viceral & Cutaneous Leishmaniasis, Lymphatic Filariasis, Malaria, Onchocerciasis, Schistosomiasis, Trichuriasis, Tuberculosis.


The Bill and Melinda Gates Foundation

MMV Pathogen Box Team:
Paul Wills
Thomas Spangenberg
Emilie Burlot
Tim Wells
Wesley van Voorhis

External Contributors:
Andreas Verras, Richard T. Clark Fellowship for World Health, Merck & Co., Inc.
Joie Garfunkle, Richard T. Clark Fellowship for World Health, Merck & Co., Inc.

Selection Committee:
Simon Campbell, Chair
Charles Mowbray, DNDi
Dale Kempf, Abbvie
Gerald Shipps, TBDA
Jeremy Burrows, MMV
Leslie Street, UCT
Paul Wyatt, University of Dundee
Peter Warner, BMGF
Tom von Geldern, Independent Consultant
Lluis Ballell-Pages, GSK

Partners & Contributors To Date:
A-WOL Consortium
Pollastri Lab
Saint Jude Children’s Research Hospital
Tuberculosis Drug Accelerator (TBDA)
TCG Lifesciences

                     Click chart to enlarge